BAM
NERV icon

Belpointe Asset Management’s Minerva Neurosciences NERV Stock Holding History

Belpointe Asset Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100
Closed -$160 – 2337
2023
Q1 		$160 Hold
100
– – ﹤0.01% 3693
2022
Q4 		$159 Buy
+100
New +$432 ﹤0.01% 3651

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Belpointe Asset Management's NERV Position: Q2 2023 in Review

Belpointe Asset Management sold out of Minerva Neurosciences (NERV) in Q2 2023, closing a stake of 100 shares — an estimated $160 sold.

Belpointe Asset Management first reported a position in NERV in Q4 2022 and held it in 2 quarters. The position peaked at $160 in Q1 2023. 19 funds tracked by Wall St. Rank hold NERV as of Q2 2023.

  • Belpointe Asset Management reported no remaining Minerva Neurosciences position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 100 Minerva Neurosciences shares in Q2 2023, an estimated $160.
  • Belpointe Asset Management first reported a position in Minerva Neurosciences in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Minerva Neurosciences position peaked at $160 in Q1 2023.
  • 19 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.